Posted by Michael Wonder on 05 May 2017
Engaging specialist oncologists in the assessment of oncology drugs in Canada
1 May 2017 - The assessment of new cancer drugs in Canada increasingly engages specialist oncology physicians. This has not always been the case.
In the 1990s, each of Canada's provinces had their own review and approval process to fund anticancer drugs, and although provinces typically drew on the clinical expertise of their provincial disease-site groups, physicians were not fully engaged in the health technology assessment process. In particular, they did not participate in the discussion of cost-effectiveness, value, or feasibility of adoption of new oncology products.
